Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of fluid and electrolyte depletion,Provision of caloric intake in patients requiring parenteral nutrition,Correction of hypoglycemia,Maintenance fluid therapy
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Dextrose: <15 minutes due to rapid cellular uptake and metabolism; sodium and chloride: no defined half-life as electrolytes are homeostatically regulated.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is rapidly metabolized via glycolysis and the Krebs cycle; sodium chloride is not metabolized but excreted renally.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal; dextrose is metabolized to CO2 and water; sodium and chloride are excreted renally with >90% reabsorption under normal conditions.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: negligible; sodium and chloride: not protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: approximately 0.2 L/kg (total body water); sodium and chloride: distribute into extracellular fluid (approx 0.2 L/kg).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
100% for intravenous route; not applicable for oral/other routes.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No specific dose adjustment for dextrose; monitor fluid and electrolyte balance. In severe renal impairment (e GFR <30 m L/min/1.73 m²), restrict volume as needed to avoid fluid overload and hyperkalemia when combined with sodium chloride.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment for Child-Pugh class; monitor glucose and fluid status. Caution in severe hepatic failure due to risk of hyperglycemia and fluid retention.
No dosage adjustment required for hepatic impairment.
Weight-based dosing: Intravenous infusion at 4-8 mg/kg/min for glucose provision; typical maintenance fluid rates: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for each additional kg. Individualize based on age, weight, and clinical status.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Monitor for fluid overload, hyperglycemia, and electrolyte disturbances. Use lower initial infusion rates (e.g., 50-100 m L/hour) and adjust based on renal function and cardiovascular status. Avoid excessive sodium load in patients with hypertension or heart failure.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Not for use in patients with intracranial or intraspinal hemorrhage, or in those with known hypersensitivity to corn or corn products (dextrose source).
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia, especially in diabetic patients,Risk of fluid overload, especially in patients with renal impairment or heart failure,Electrolyte imbalances (e.g., hypernatremia, hyperchloremia) with excessive administration,Use with caution in patients with hepatic disease, as dextrose may exacerbate encephalopathy
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia,Hypernatremia,Intracranial or intraspinal hemorrhage,Known hypersensitivity to corn or corn products,Severe hypokalemia (can worsen with dextrose infusion)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. However, as this solution provides dextrose (sugar) and sodium, patients with diabetes or salt-restricted diets should be monitored. Avoid concurrent intake of high-sugar or high-salt foods without medical advice.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglycemia-related congenital anomalies. Intravenous administration may be necessary in third trimester for fluid maintenance. No direct fetal toxicity.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Dextrose and sodium chloride are normal constituents of breast milk. Intravenous infusion does not alter milk composition significantly. M/P ratio not applicable. Considered compatible with breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dosing adjustment required solely for pregnancy. However, increased plasma volume in pregnancy may require careful monitoring of fluid balance to avoid overload. Adjust rate and volume based on clinical status, not pregnancy per se.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Use with caution in patients with congestive heart failure, renal impairment, or conditions causing sodium retention. Monitor serum glucose and electrolytes, especially in diabetic patients or those receiving parenteral nutrition. Avoid in patients with hyperglycemia, hyponatremia, or fluid overload. Do not administer simultaneously with blood products due to risk of hemolysis. Inspect for particulate matter and discoloration before use; discard if present.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Inform your healthcare provider if you have diabetes, high blood pressure, heart or kidney disease, or fluid retention.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing.,Tell your doctor if you experience headache, confusion, muscle cramps, or swelling of hands/ankles.,This solution provides sugar and salt; discuss any dietary restrictions with your doctor.,Do not use the solution if it is cloudy, discolored, or contains particles.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglyc. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.